Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO
Acelyrin said Monday that its lead drug izokibep failed to meet the primary endpoint in a Phase IIb/III trial in patients with hidradenitis suppurativa — a chronic inflammatory condition that causes painful nodules and abscesses to form under the skin.
It’s the Los Angeles biotech’s first big clinical readout since it went public in May, and the news was brutal to its shares $SLRN — they fell 64% in after-hours trading Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.